Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis
The Regulatory Reality of 2026: What Actually Changed In late 2023, the FDA moved 19 peptides, including BPC-157, to what's known as "Category 2" status under its framework for bulk drug substances used in compounding, identifying them as substances that "may present significant safety risks." The concern, as stated in FDA guidance, centered on the limited large-scale human data and questions about immunogenicity
If you're using a strong retinoid or exfoliant, it's best to be cautious, as layering too many actives may cause irritation
Metformin and autoimmunity: a new deal of an old drug
Your body often adjusts to these medications over time, and many side effects become less bothersome after a few weeks
Space morning and evening doses approximately 12 hours apart